HOME >> MEDICINE >> NEWS
Where do new therapies work best?

An observational study to investigate how new therapies for rheumatic diseases perform across different conditions has revealed that they may be more successful in certain conditions. The data is presented today at the Annual European Congress of Rheumatology in Amsterdam, the Netherlands. An increasing proportion of patients with rheumatic conditions such as ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) now receive anti-TNF treatment a newer group of drugs which are used to reduce inflammation and manage disease activity*. Study lead Dr Marte Heiberg, of the Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, told delegates: "Many studies have focused on efficacy of these drugs, however less is known about comparative real life performance of these drugs across different diagnostic groups".

The study was conducted across 5 Norwegian Rheumatology Departments and included 796 RA patients, 162 PsA patients and 211 patients with a diagnosis of AS. All patients were on an anti-TNF treatment regimen of infliximab, etanercept or adalimumab +/- methotrexate (MTX). The primary outcome was the number of patients still on therapy at one year known as the adherence to therapy. RA was used as the reference group and within each diagnostic group the adherence to anti-TNF monotherapy versus TNF+MTX was compared.

The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients
'"/>

Contact: Mia Gannedahl
mia_gannedahl@uk.cohnwolfe.com
44-207-331-2325
European League Against Rheumatism
22-Jun-2006


Page: 1 2

Related medicine news :

1. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
2. Where is the most dangerous place to travel over the holiday?
3. Where should I have my outpatient surgery?
4. Where are medical graduates practising and why?
5. Where the brain organizes actions
6. Where we change our mind
7. Where your brain wires itself to like (name your favorite brand)
8. Where lifes memories are stored
9. Future therapies for stroke may block cell death
10. Antifolate therapies found effective against certain type of malaria
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Where new therapies work best

(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
(Date:10/22/2014)... Influenza will affect as many as 200,000 people this year ... as high as 49,000 people.  The main way ... to person in respiratory droplets of coughs and sneezes. ... kills much fewer people each year than the Flu. The ... sweat, saliva, blood and other bodily fluids. The Ebola virus ...
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) ... novel investigational drug for cancer, is designed for injection ... effects. Its oncology focus is on melanoma, breast cancer ... 2 trials of PV-10 as a therapy for metastatic ... atopic dermatitis and psoriasis. This summer, ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
Cached News: